

VOLUME 29 NUMBER 2 April 2023

pISSN 2287-2728  
eISSN 2387-285X

# CLINICAL and MOLECULAR HEPATOLOGY

The forum for latest knowledge of hepatobiliary diseases



Asia clinical practice guidelines for HCC

Single-cell phenotypes of immune cells in NAFLD

Global burden of primary liver cancer

Factors of unrecognized cirrhosis in HCC patients

## Editorial

# Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease

Maamon Basheer<sup>1</sup>, Mohamed Naffaa<sup>2</sup>, and Nimer Assy<sup>1,2,3</sup>

<sup>1</sup>Internal Medicine Department, <sup>2</sup>Rheumatology Unit, Galilee Medical Center, Nahariya; <sup>3</sup>Azrieli Faculty of Medicine in the Galilee, Bar-Ilan, University, Safed, Israel

**Keywords:** Fatty liver; Non alcoholic steato-hepatitis; Liver fibrosis; Non invasive markers

See Article on <https://doi.org/10.3350/cmh.2022.0348>

The search for reliable and non-invasive biomarkers of liver fibrosis has been a focus of intense medical research, with the aim of improving patient outcomes through early diagnosis and effective treatment. The purpose of this editorial is to raise awareness about the importance of non-invasive biomarkers for liver fibrosis and the impact of fibrosis on overall well-being.

Various predictive tests have been developed as non-invasive tests alternative to either imaging or liver biopsy.<sup>1-3</sup> The Fibrosis Risk Stratification includes three levels: Low risk if (fibrosis-4 [FIB-4]: <1.30, liver stiffness measurement [LSM] <8 kPa, enhanced liver fibrosis [ELF] <7.7); Indeterminate risk if (FIB-4: 1.30–2.67, LSM 8–12 kPa, ELF 7.7–9.8) and high risk if (FIB-4: >2.67, LSM >12 kPa, ELF >9.8). However, these tests have often not met quality metrics for diagnostic tests, leaving the clinician with a fair degree of uncertainty.<sup>4-8</sup> In this issue of the *Clinical and Molecular Hepatology*, Reinson et al.<sup>9</sup> clearly showed that there are several biomarkers that have been studied for their ability to identify individuals with F2-

F3 degree of fibrosis in the liver. These markers includes FibroTest, NAFLD fibrosis score, Fibro Scan, acoustic radiation force impulse, Aspartate aminotransferase-to-Platelet Ratio Index (APRI), magnetic resonance elastography (MRE), FibroScan-AST (FAST) score and ELF tests.<sup>9</sup> It is important to note that these biomarkers are not perfect and their performance may vary depending on age, body mass index and the underlying cause of fibrosis. Therefore, it is important to use them in combination with other diagnostic tools, such as clinical examination and imaging exams, to make a definitive decision.

Machine learning algorithms have been studied as a future potential alternative for identifying individuals with F2-F3 fibrosis or higher; But their performance ability needs to be confirmed.<sup>10,11</sup>

Noninvasive serum biomarkers have been studied for their utility in predicting liver-related outcomes.<sup>11</sup> Serial measurement of specific biomarkers could be used in order to monitor liver disease progression and response to treatment.<sup>11</sup> Some examples include tracking fibrosis by using FibroTest and APRI, monitoring cirrhosis by prothrombin time, and monitoring liver cancer by  $\alpha$ -fetoprotein. Increase of 20% in

### Corresponding author : Nimer Assy

Azrieli Faculty of Medicine in the Galilee, Bar-Ilan, University, Henrietta Szold St 8, Safed 1311502, Israel  
Tel: +97249107748, Fax: +97249107158, E-mail: [nimera@gmc.gov.il](mailto:nimera@gmc.gov.il)  
<https://orcid.org/0000-0002-2279-6041>

Editor: Seung Up Kim, Yonsei University College of Medicine, Korea

Received : Feb. 6, 2023 / Revised : Feb. 7, 2023 / Accepted : Feb. 8, 2023

vibration controlled transient elastography ( $\geq 16.6$  kPa) predicts progression to cirrhosis and  $\geq 30.7$  kPa predicts decompensation. Increase of 15% in MRE is associated with fibrosis progression and increase of 19% in MRE associated with poor outcomes.<sup>12-14</sup> In viral hepatitis, measuring viral load, liver enzymes and FibroTest or FIB-4 at different intervals can help to assess the effectiveness of antiviral therapy. It is also important to consider that some biomarkers may not significantly change even with an effective treatment, or may take longer time to show improvement.<sup>12-14</sup>

Non-invasive biomarkers can be also useful tools in drug trials for non-alcoholic steatohepatitis (NASH). These tools could help in monitoring progression and regression of liver fibrosis. However, it is important to use them in conjunction with other diagnostic tools and to have a clear understanding of their limitations and potential biases. Higher baseline, greater change in ELF ( $>9.76$ ) is associated with an increased risk of progression to cirrhosis. ELF greater than 11.3 predicts liver-related clinical events.<sup>15</sup>

Liver stiffness measurement by transient elastography, platelet counts and spleen stiffness could be also used for assessment of the degree of portal hypertension and the extent of liver fibrosis.<sup>16</sup> A level of transient elastography above 15 kPa and platelet counts below 150K indicate significant portal hypertension.<sup>16</sup>

How best can I identify who needs to be treated without a liver biopsy?

There are three scores to answer that:

1. The FAST score (Fibroscan AST) provides an efficient way to non-invasively identify patients at risk of progressive NASH for clinical trials or treatments, and thereby reduce unnecessary liver biopsy in patients unlikely to have significant disease. Performance of FAST score is good with AUC 0.71, positive predictive value (PPV) 33-85% and negative predictive value (NPV) 73-100%.<sup>17</sup>

2. The MAST score (MRI-PDFF-AST) outperforms previous scores with AUC 0.93; In the validation cohorts, the 90% specificity cut-off of 0.242 corresponded to a sensitivity of 75%, PPV of 50% and NPV of 97%, whereas the 90% sensitivity

cut-off of 0.165 corresponded to a specificity of 72%, PPV of 29%, and NPV of 98%.<sup>18</sup>

3. Finally the MRE combined with FIB-4: (FIB-4 [if  $\geq 1.6$ ]+MRE  $\geq 3.3$  kPa) score is superior to FAST in detecting patients "at risk" for NASH among patients with biopsy-proven NAFLD with AUC 0.88.<sup>19</sup>

Future Perspective: metabolomics, lipid omics, and multiomics (gut microbiome) studies could help the clinicians in identify biomarkers associated with the pathophysiology of NAFLD and NASH. Integration of artificial intelligence and machine learning techniques to improve diagnostic accuracy and to develop personalized treatment plans for patients.

These biomarkers offer a more reliable, non-invasive, and cost-effective alternative to liver biopsy for diagnosing liver fibrosis. Combining several tests and scores, and creating charts for risk stratification and management, help the primary physician manage such patients and refer them to specialized centers.

### Authors' contribution

NIMER Assy wrote the manuscript. Maamon Basheer and Mohamed Naffah revised it.

### Conflicts of Interest

The authors have no conflicts to disclose.

### REFERENCES

1. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. *JAMA* 2015;313:2263-2273.
2. Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. *Lancet Gastroenterol Hepatol* 2020;5:362-373. Erratum in: *Lancet Gastroenterol Hepatol* 2020;5:e3.
3. Harrison SA, Ratzliff V, Boursier J, Francque S, Bedossa P, Majd Z,

### Abbreviations:

FIB-4, fibrosis-4; LSM, liver stiffness measurement; ELF, enhanced liver fibrosis; ARFI, acoustic radiation force impulse; NFS, NAFLD fibrosis score; APRI, aspartate aminotransferase-to-platelet ratio index; MRE, magnetic resonance elastography of liver; FAST score, FibroScan-AST score; VCTE, vibration controlled transient elastography; NASH, non-alcoholic steatohepatitis; PPV&NPV, positive and negative predictive values; NAFLD, non-alcoholic fatty liver disease; MAST score, The MRI-aspartate aminotransferase score; MEFIB, MRE combined with FIB-4

- et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. *Lancet Gastroenterol Hepatol* 2020;5:970-985.
4. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? *Hepatology* 2010;51:373-375. Erratum in: *Hepatology* 2010;51:1868.
  5. Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* 2013;145:782-789.e4.
  6. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. *Gut* 2008;57:1441-1447.
  7. Boursier J, de Ledinghen V, Poynard T, Guéchet J, Carrat F, Leroy V, et al.; ARDENT group; AFEF. An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. *J Hepatol* 2015;62:807-815.
  8. Alkhoury N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. *Gastroenterol Hepatol (N Y)* 2012;8:661-668.
  9. Reinson T, Buchanan RM, Byrne CD. Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future. *Clin Mol Hepatol* 2022 Nov 22. doi: 10.3350/cmh.2022.0348.
  10. Sarvestany SS, Kwong JC, Azhie A, Dong V, Cerocchi O, Ali AF, et al. Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study. *Lancet Digit Health* 2022;4:e188-e199.
  11. Yilmaz Y, Toraman AE, Alp C, Doğan Z, Keklikkiran C, Stepanova M, et al. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. *Aliment Pharmacol Ther* 2023;57:215-223.
  12. Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. *J Hepatol* 2022;76:1362-1378.
  13. Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, et al. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. *Hepatology* 2020;71:849-860.
  14. Harrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. *Hepatology* 2022;76:1862-1879.
  15. Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. *J Hepatol* 2022;76:1263-1278.
  16. Reiberger T, Hofer BS. The Baveno VII concept of cirrhosis recompensation. *Dig Liver Dis* 2023 Jan 14. doi: 10.1016/j.dld.2022.12.014.
  17. Nouredin N, Alkhoury N, Brown KA, Nouredin M. Driving non-alcoholic steatohepatitis forward using the FibroScan aspartate aminotransferase score, but obey the traffic lights. *Hepatology* 2020;72:2228-2230.
  18. Jung J, Loomba RR, Imajo K, Madamba E, Gandhi S, Bettencourt R, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. *Gut* 2021;70:1946-1953.
  19. Kim BK, Tamaki N, Imajo K, Yoneda M, Sutter N, Jung J, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. *J Hepatol* 2022;77:1482-1490.